AcuCort’s vision is that Dexa ODF will be globally commercialized, be well integrated and used in the treatment/risk management of acute allergic reactions and croup in children, and see wide use against chemotherapy-induced nausea and vomiting (CINV.)
AcuCort shall develop and commercialize Dexa ODF supported by a global network of licensees and/or distributors. AcuCort shall also identify, develop and commercialize complementary smart products with short time to launch that are based on existing substances.
AcuCort AB was founded in 2006 as a subsidiary of DuoCort AB. 2011 marked a new beginning for AcuCort and its development project, as the life science company P.U.L.S. AB acquired the company from DuoCort AB. From then until April 2017 AcuCort has been managed as a part of the PULS group, now known as AQILION AB. Following a successful IPO (Initial Public Offering), AcuCort was listed in Sweden.
AcuCort develops and commercializes Dexa ODF, a fast-dissolving oral film containing the glucocorticoid dexamethasone. The new innovative product can among other things be used for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting (CINV).
In the development of Dexa ODF the advantages of the frequently used and well-documented substance, dexamethasone and the fast-dissolving film have been combined in a product that is tailored for rapid access and relief in acute situations.
End of March and early in April, 2017, AcuCort carried out a successful emission amounting to MSEK 14 after financing costs. The issue was subscribed to by more than 900 investors. The majority owner, P.U.L.S. AB (now AQILION AB) also took part in the issue.
AcoCort AB:s share has been listed on Spotlight Stock Market since (24/04 2017) under the ticker (ACUC) and is traded through banks and stockbrokers.
The capital raised is mainly used for finalization of product development, scaling up of production, and production of GMP grade batches for use in the pivotal bioequivalence studies in the EU and the US. The company aims for market approval of Dexa ODF in 2019 in the EU and in 2020 in the US. Read more about the development of the project on the page Research & Development.
AcuCort Dexa ODF is protected by two patent families (approved patents and patent applications) and a considerable amount of technical know-how concerning dexamethasone and oral films.
About Aqilion ‒ the majority owner
The majority owner Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB changed its name to AQILION AB in the beginning of 2019. The name change marks a new phase in the development of the company, with a new strategy and identity.
Aqilion is a Swedish life science company that focuses on pharmaceutical projects with potential to improve quality of life for patients, while generating value for health services and society.
Read more at www.aqilion.com.